ARTICLE | Company News
Almirall acquires U.S. dermatology products from Allergan
August 17, 2018 3:20 AM UTC
Almirall S.A. (Madrid:ALM) will acquire a portfolio of five dermatology products marketed in the U.S. from Allergan plc (NYSE:AGN) for $550 million in cash.
The portfolio, which generated 1H18 sales of $70 million, includes acne and inflammation drugs Aczone dapsone, Tazorac tazorotene, Azelex azelaic acid and Cordran Tape fludroxycortide. The deal also includes acne candidate Seysara sarecyline, an oral tetracycline-derived antibiotic for which Almirall expects U.S. approval in 4Q18. The companies did not respond to inquiries...